Los Angeles Capital Management LLC reduced its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 57.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,438 shares of the company's stock after selling 59,567 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.08% of Stoke Therapeutics worth $479,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Barclays PLC raised its holdings in shares of Stoke Therapeutics by 145.3% in the 3rd quarter. Barclays PLC now owns 79,740 shares of the company's stock valued at $980,000 after buying an additional 47,239 shares during the period. Geode Capital Management LLC lifted its position in shares of Stoke Therapeutics by 9.7% during the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company's stock worth $10,705,000 after purchasing an additional 76,661 shares in the last quarter. State Street Corp boosted its stake in shares of Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company's stock valued at $21,248,000 after purchasing an additional 137,145 shares during the period. RTW Investments LP increased its holdings in Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after purchasing an additional 427,447 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in Stoke Therapeutics by 1,589.7% in the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company's stock worth $936,000 after acquiring an additional 71,647 shares during the last quarter.
Wall Street Analysts Forecast Growth
STOK has been the topic of a number of research analyst reports. HC Wainwright raised their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. Chardan Capital restated a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, February 19th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics has an average rating of "Buy" and a consensus price target of $23.00.
View Our Latest Stock Analysis on STOK
Stoke Therapeutics Trading Down 1.6 %
Shares of Stoke Therapeutics stock traded down $0.13 during mid-day trading on Friday, hitting $8.02. 208,628 shares of the stock were exchanged, compared to its average volume of 816,577. Stoke Therapeutics, Inc. has a twelve month low of $5.60 and a twelve month high of $17.58. The company has a 50-day simple moving average of $9.91 and a 200 day simple moving average of $11.90. The stock has a market capitalization of $424.80 million, a price-to-earnings ratio of -3.83 and a beta of 0.99.
Insider Activity at Stoke Therapeutics
In related news, General Counsel Jonathan Allan sold 13,666 shares of the company's stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $13.61, for a total transaction of $185,994.26. Following the completion of the transaction, the general counsel now owns 21,476 shares of the company's stock, valued at approximately $292,288.36. This represents a 38.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $88,150.14. Following the completion of the transaction, the chief executive officer now owns 61,885 shares in the company, valued at approximately $803,886.15. This trade represents a 9.88 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 23,038 shares of company stock worth $307,737. 11.30% of the stock is currently owned by insiders.
About Stoke Therapeutics
(
Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
See Also
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
